{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T20:21:28Z","timestamp":1693599688221},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13722-015-0041-6","type":"journal-article","created":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T20:26:47Z","timestamp":1444768007000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of hepatitis C status on 20-year mortality of patients with substance use disorders"],"prefix":"10.1186","volume":"10","author":[{"given":"Anthony J.","family":"Accurso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darius A.","family":"Rastegar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon R.","family":"Ghazarian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael I.","family":"Fingerhood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,13]]},"reference":[{"key":"41_CR1","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1001\/archinte.1993.00410170111011","volume":"153","author":"MI Fingerhood","year":"1993","unstructured":"Fingerhood MI. Prevalence of hepatitis C in a chemically dependent population. Arch Intern Med. 1993;153:2025.","journal-title":"Arch Intern Med"},{"key":"41_CR2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00005792-199507000-00005","volume":"74","author":"DL Thomas","year":"1995","unstructured":"Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore). 1995;74:212\u201320.","journal-title":"Medicine (Baltimore)."},{"key":"41_CR3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2105\/AJPH.91.1.46","volume":"91","author":"J Lorvick","year":"2001","unstructured":"Lorvick J, Kral AH, Seal K, Gee L, Edlin BR. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health. 2001;91:46\u20137.","journal-title":"Am J Public Health."},{"issue":"Suppl 1","key":"41_CR4","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/00042560-199802001-00004","volume":"18","author":"RS Garfein","year":"1998","unstructured":"Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(Suppl 1):S11\u20139.","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol."},{"key":"41_CR5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jama.284.4.450","volume":"284","author":"DL Thomas","year":"2000","unstructured":"Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450\u20136.","journal-title":"JAMA"},{"issue":"Suppl 1","key":"41_CR6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0168-8278(99)80369-9","volume":"31","author":"A Alberti","year":"1999","unstructured":"Alberti A, Chemello L, Benvegnu L. Natural history of hepatitis C. J Hepatol. 1999;31(Suppl 1):17\u201324.","journal-title":"J Hepatol."},{"key":"41_CR7","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","volume":"36","author":"LB Seeff","year":"2002","unstructured":"Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35\u201346.","journal-title":"Hepatology."},{"key":"41_CR8","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.510300409","volume":"30","author":"Y Benhamou","year":"1999","unstructured":"Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The multivirc group. Hepatology. 1999;30:1054\u20138.","journal-title":"Hepatology"},{"key":"41_CR9","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM198911303212204","volume":"321","author":"AM Bisceglie Di","year":"1989","unstructured":"Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989;321:1506\u201310.","journal-title":"N Engl J Med."},{"key":"41_CR10","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJM198911303212203","volume":"321","author":"GL Davis","year":"1989","unstructured":"Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis interventional therapy group. N Engl J Med. 1989;321:1501\u20136.","journal-title":"N Engl J Med"},{"key":"41_CR11","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.gastro.2013.10.057","volume":"146","author":"GT Everson","year":"2014","unstructured":"Everson GT, Sims KD, Rodriguez-Torres M, et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology. 2014;146:420\u20139.","journal-title":"Gastroenterology"},{"key":"41_CR12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1306227","volume":"370","author":"KV Kowdley","year":"2014","unstructured":"Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370:222\u201332.","journal-title":"N Engl J Med"},{"key":"41_CR13","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2013.109309","volume":"310","author":"A Osinusi","year":"2013","unstructured":"Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013;310:804\u201311.","journal-title":"JAMA"},{"key":"41_CR14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1208809","volume":"368","author":"F Poordad","year":"2013","unstructured":"Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013;368:45\u201353.","journal-title":"N Engl J Med."},{"key":"41_CR15","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa1213557","volume":"369","author":"S Zeuzem","year":"2013","unstructured":"Zeuzem S, Soriano V, Asselah T, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med. 2013;369:630\u20139.","journal-title":"N Engl J Med"},{"key":"41_CR16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7326\/0003-4819-158-2-201301150-00574","volume":"158","author":"R Chou","year":"2013","unstructured":"Chou R, Cottrell EB, Wasson N, Rahman B, Guise JM. Screening for hepatitis C virus infection in adults: a systematic review for the U.S. preventive services task force. Ann Intern Med. 2013;158:101\u20138.","journal-title":"Ann Intern Med"},{"key":"41_CR17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.7326\/0003-4819-159-5-201309030-00672","volume":"159","author":"VA Moyer","year":"2013","unstructured":"Moyer VA. U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. preventive services task force recommendation statement. Ann Intern Med. 2013;159:349\u201357.","journal-title":"Ann Intern Med"},{"key":"41_CR18","doi-asserted-by":"crossref","first-page":"364","DOI":"10.7326\/0003-4819-159-5-201309030-00675","volume":"159","author":"Q Ngo-Metzger","year":"2013","unstructured":"Ngo-Metzger Q, Ward JW, Valdiserri RO. Expanded hepatitis C virus screening recommendations promote opportunities for care and cure. Ann Intern Med. 2013;159:364\u20135.","journal-title":"Ann Intern Med."},{"key":"41_CR19","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-157-9-201211060-00529","volume":"157","author":"BD Smith","year":"2012","unstructured":"Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945\u20131965: recommendations from the centers for disease control and prevention. Ann Intern Med. 2012;157:817\u201322.","journal-title":"Ann Intern Med"},{"key":"41_CR20","doi-asserted-by":"crossref","unstructured":"[Anonymous]. Summaries for patients: Screening for hepatitis C virus infection in adults: U.S. preventive services task force recommendation statement. Ann Intern Med. 2013; 159:I-32.","DOI":"10.7326\/0003-4819-159-5-201309030-00677"},{"key":"41_CR21","doi-asserted-by":"crossref","unstructured":"[Anonymous]. Summaries for patients. hepatitis C virus testing of persons born during 1945\u20131965: Recommendations from the centers for disease control and prevention. Ann Intern Med. 2012; 157:I-38.","DOI":"10.7326\/0003-4819-157-9-201211060-00530"},{"key":"41_CR22","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","volume":"370","author":"KV Kowdley","year":"2014","unstructured":"Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12\u00a0weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879\u201388.","journal-title":"N Engl J Med"},{"key":"41_CR23","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/gutjnl-2014-307498","volume":"64","author":"C Hezode","year":"2015","unstructured":"Hezode C, Hirschfield GM, Ghesquiere W, et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 2015;64:948\u201356.","journal-title":"Gut."},{"key":"41_CR24","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/hep.27039","volume":"59","author":"NS Reau","year":"2014","unstructured":"Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology. 2014;59:1246\u20139.","journal-title":"Hepatology"},{"key":"41_CR25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ypmed.2006.10.003","volume":"44","author":"B Smyth","year":"2007","unstructured":"Smyth B, Hoffman V, Fan J, Hser YI. Years of potential life lost among heroin addicts 33\u00a0years after treatment. Prev Med. 2007;44:369\u201374.","journal-title":"Prev Med"},{"key":"41_CR26","unstructured":"CDC National Center for Health Statistics. 1993 ABRIDGED LIFE TABLE\u2014TOTAL POPULATION. http:\/\/www.cdc.gov\/nchs\/data\/statab\/lewk1_93.pdf . Accessed 9 Dec 14."},{"key":"41_CR27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/00952990.2011.553977","volume":"37","author":"PK Muhuri","year":"2011","unstructured":"Muhuri PK, Gfroerer JC. Mortality associated with illegal drug use among adults in the United States. Am J Drug Alcohol Abuse. 2011;37:155\u201364.","journal-title":"Am J Drug Alcohol Abuse."},{"key":"41_CR28","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1399-6576.2008.01597.x","volume":"52","author":"OMS Fredheim","year":"2008","unstructured":"Fredheim OMS, et al. Clinical pharmacology of methadone for pain. Acta Anaesthesiol Scand. 2008;52:879\u201389.","journal-title":"Acta Anaesthesiol Scand"},{"key":"41_CR29","doi-asserted-by":"crossref","first-page":"387","DOI":"10.7326\/0003-4819-150-6-200903170-00103","volume":"150","author":"MJ Krantz","year":"2009","unstructured":"Krantz MJ. QTc interval screening in methadone treatment. Ann Intern Med. 2009;150:387.","journal-title":"Ann Intern Med."},{"key":"41_CR30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drugalcdep.2009.03.020","volume":"104","author":"JR Bell","year":"2009","unstructured":"Bell JR, Butler B, Lawrance A, Batey R, Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend. 2009;104:73\u20137.","journal-title":"Drug Alcohol Depend."},{"key":"41_CR31","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamainternmed.2014.6294","volume":"175","author":"WA Ray","year":"2015","unstructured":"Ray WA, Chung CP, Murray KT, Cooper WO, Hall K, Stein CM. Out-of-hospital mortality among patients receiving methadone for noncancer pain. JAMA Intern Med. 2015;175:420.","journal-title":"JAMA Intern Med."},{"issue":"786\u2013792","key":"41_CR32","first-page":"e1","volume":"9","author":"B Grady","year":"2011","unstructured":"Grady B, van den Berg C, van der Helm J, et al. No impact of hepatitis C virus infection on mortality among drug users during the first decade after seroconversion. Clin Gastroenterol Hepatol. 2011;9(786\u2013792):e1.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"41_CR33","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1111\/j.1360-0443.2011.03575.x","volume":"106","author":"A Gibson","year":"2011","unstructured":"Gibson A, Randall D, Degenhardt L. The increasing mortality burden of liver disease among opioid-dependent people: Cohort study. Addiction. 2011;106:2186\u201392.","journal-title":"Addiction."},{"key":"41_CR34","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2893.2010.01279.x","volume":"18","author":"J Grebely","year":"2011","unstructured":"Grebely J, Raffa JD, Lai C, et al. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. J Viral Hepat. 2011;18:32\u201341.","journal-title":"J Viral Hepat."},{"key":"41_CR35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2012.08.024","volume":"58","author":"KB Kielland","year":"2013","unstructured":"Kielland KB, Skaug K, Amundsen EJ, Dalgard O. All-cause and liver-related mortality in hepatitis C infected drug users followed for 33\u00a0years: a controlled study. J Hepatol. 2013;58:31\u20137.","journal-title":"J Hepatol"},{"key":"41_CR36","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","volume":"206","author":"MH Lee","year":"2012","unstructured":"Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206:469\u201377.","journal-title":"J Infect Dis."},{"key":"41_CR37","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1093\/aje\/kwr318","volume":"175","author":"JL Evans","year":"2012","unstructured":"Evans JL, Tsui JI, Hahn JA, Davidson PJ, Lum PJ, Page K. Mortality among young injection drug users in San Francisco: a 10-year follow-up of the UFO study. Am J Epidemiol. 2012;175:302\u20138.","journal-title":"Am J Epidemiol"},{"key":"41_CR38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.drugalcdep.2014.12.019","volume":"147","author":"S Larney","year":"2015","unstructured":"Larney S, Bohnert AS, Ganoczy D, et al. Mortality among older adults with opioid use disorders in the veteran\u2019s health administration, 2000\u20132011. Drug Alcohol Depend. 2015;147:32\u20137.","journal-title":"Drug Alcohol Depend"},{"key":"41_CR39","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jhep.2014.09.001","volume":"62","author":"EJ Aspinall","year":"2015","unstructured":"Aspinall EJ, Hutchinson SJ, Janjua NZ, et al. Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment. J Hepatol. 2015;62:269\u201377.","journal-title":"J Hepatol."},{"key":"41_CR40","doi-asserted-by":"crossref","first-page":"19296","DOI":"10.7448\/IAS.17.1.19296","volume":"17","author":"K Hayashi","year":"2014","unstructured":"Hayashi K, Milloy MJ, Wood E, Dong H, Montaner JS, Kerr T. Predictors of liver-related death among people who inject drugs in vancouver, canada: a 15-year prospective cohort study. J Int AIDS Soc. 2014;17:19296.","journal-title":"J Int AIDS Soc."},{"issue":"109","key":"41_CR41","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/add.12367","volume":"2013","author":"D Fuster","year":"2014","unstructured":"Fuster D, Cheng DM, Quinn EK, et al. Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems. Addiction. 2014;2013(109):62\u201370.","journal-title":"Addiction."},{"key":"41_CR42","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2012.06.010","volume":"57","author":"V Hernando","year":"2012","unstructured":"Hernando V, Perez-Cachafeiro S, Lewden C, et al. All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. J Hepatol. 2012;57:743\u201375.","journal-title":"J Hepatol."},{"key":"41_CR43","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1097\/QAD.0000000000000377","volume":"28","author":"MB Klein","year":"2014","unstructured":"Klein MB, Rollet-Kurhajec KC, Moodie EE, et al. Mortality in HIV-hepatitis C co-infected patients in canada compared to the general canadian population (2003\u20132013). AIDS. 2014;28:1957\u201365.","journal-title":"AIDS."},{"key":"41_CR44","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMp1314965","volume":"370","author":"NE Morden","year":"2014","unstructured":"Morden NE, Colla CH, Sequist TD, Rosenthal MB. Choosing wisely\u2014the politics and economics of labeling low-value services. N Engl J Med. 2014;370:589\u201392.","journal-title":"N Engl J Med"},{"key":"41_CR45","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jsat.2007.12.008","volume":"35","author":"MT French","year":"2008","unstructured":"French MT, Popovici I, Tapsell L. The economic costs of substance abuse treatment: Updated estimates and cost bands for program assessment and reimbursement. J Subst Abuse Treat. 2008;35:462\u20139.","journal-title":"J Subst Abuse Treat."},{"key":"41_CR46","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1001\/archpsyc.58.5.503","volume":"58","author":"YI Hser","year":"2001","unstructured":"Hser YI, Hoffman V, Grella CE, Anglin MD. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry. 2001;58:503\u20138.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"41_CR47","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2105\/AJPH.77.3.347","volume":"77","author":"GW Joe","year":"1987","unstructured":"Joe GW, Simpson DD. Mortality rates among opioid addicts in a longitudinal study. Am J Public Health. 1987;77(3):347\u20138.","journal-title":"Am J Public Health"},{"key":"41_CR48","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2105\/AJPH.2010.197038","volume":"101","author":"CK Scott","year":"2011","unstructured":"Scott CK, Dennis ML, Laudet A, Funk RR, Simeone RS. Surviving drug addiction: the effect of treatment and abstinence on mortality. Am J Public Health. 2011;101:737\u201344.","journal-title":"Am J Public Health."}],"container-title":["Addiction Science & Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-015-0041-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T14:00:03Z","timestamp":1567260003000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ascpjournal.org\/content\/10\/1\/20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,13]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["41"],"URL":"https:\/\/doi.org\/10.1186\/s13722-015-0041-6","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,13]]},"article-number":"20"}}